

Data Supplement for Crawford et al., The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial. Am J Psychiatry (doi: 10.1176/appi.ajp.2018.17091006)

TABLE S1. Total ZAN-BPD scores at baseline, 12, 24, and 52 weeks

	Lamotrigine	Standard deviation	Placebo	Standard deviation
ZAN-BPD score at baseline				
Mean	16.6	5.8	17.4	6.2
N	135		138	
ZAN-BPD score at 12 weeks				
Mean	11.5	5.7	11.5	7.1
N	111		104	
ZAN-BPD score at 24 weeks				
Mean	11.9	6.1	11.9	7.0
N	98		98	
ZAN-BPD score at 52 weeks				
Mean	11.3	6.6	11.5	7.7
N	97		98	

TABLE S2. Beck Depression Inventory scores at baseline, 12, 24, and 52 weeks

	Lamotrigine	Standard deviation	Placebo	Standard deviation
Depression score at baseline				
Mean	39.8	11.7	38.4	10.2
N	135		138	
Depression score at 12 weeks				
Mean	29.9	15.7	29.0	14.5
N	110		104	
Depression score at 24 weeks				
Mean	30.7	15.1	29.9	15.1
N	98		97	
Depression score at 52 weeks				
Mean	28.8	16.1	28.7	15.5
N	92		88	

TABLE S3. Deliberate self-harm at baseline, 12, 24, and 52 weeks

	Lamotrigine (N=137)	Placebo (N=139)
Self-harm at baseline		
No	39 (28%)	51 (37%)
Yes	96 (70%)	87 (63%)
Unknown	2 (2%)	1 (<0.5%)
Self-harm at 12 weeks		
No	59 (54%)	62 (60%)
Yes	51 (46%)	41 (40%)
Unknown	1 (<0.5%)	1 (<0.5%)
Self-harm at 24 weeks		
No	56 (57%)	60 (62%)
Yes	42 (43%)	37 (38%)
Unknown	0	1 (<0.5%)
Self-harm at 52 weeks		
No	46 (47%)	50 (51%)
Yes	45 (46%)	38 (39%)
Unknown	6 (7%)	10 (10%)

All data are N (%) unless otherwise indicated.

Denominators are the total number participants who completed the individual follow-up.

TABLE S4. Social Functioning Questionnaire Scores at baseline, 12, 24, and 52 weeks

	Lamotrigine	Standard deviation	Placebo	Standard deviation
Social function at baseline				
Mean	15.0	4.1	14.9	4.5
N	135		137	
Social function at 12 weeks				
Mean	12.6	4.5	12.6	5.2
N	110		104	
Social function at 24 weeks				
Mean	11.8	4.3	12.2	4.9
N	98		97	
Social function at 52 weeks				
Mean	12.4	4.3	12.3	4.9
N	91		88	

TABLE S5. Scores on ZAN-BPD subscales at baseline and 52 weeks

	Baseline [^]		52-week follow-up [^]		*Adjusted difference in means	95% Confidence interval	p-value
	Mean	Standard deviation	Mean	Standard deviation			
ZAN-BPD affective disturbance subscore							
Lamotrigine	6.9	2.2	4.7	2.8	-0.1	-0.9, 0.7	0.850
Placebo	7.2	2.4	4.9	3.1	—		
ZAN-BPD cognitive disturbance subscore							
Lamotrigine	4.0	2.0	2.7	2.2	0.1	-0.4, 0.7	0.615
Placebo	4.3	2.0	2.6	2.1	—		
ZAN-BPD impulsivity subscore							
Lamotrigine	3.0	2.1	2.1	2.0	-0.1	-0.6, 0.5	0.824
Placebo	3.0	1.8	2.1	2.1	—		
ZAN-BPD disturbed relationship subscore							
Lamotrigine	2.7	1.9	1.7	1.8	0	-0.5, 0.5	0.982
Placebo	2.9	2.0	1.8	2.0	—		

*Adjusted by site, baseline ZAN-BPD score, severity of personality disorder and extent of bipolarity.

[^] Data from 195 participants were included in the primary analysis model.